Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Weight-Loss drug zovaglutide enters final testing phase

NCT ID NCT07230119

Disease control Sponsor: Beijing QL Biopharmaceutical Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This Phase 3 trial tests whether zovaglutide, given as a shot every 4 weeks, helps people with overweight or obesity lose weight. About 744 adults will receive either the drug or a placebo for 52 weeks. The study measures how much weight they lose and how many achieve at least 5% weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
zovaglutide
What this could lead to
If successful, zovaglutide could offer a new, effective weight-loss option for people with overweight or obesity, helping them lose significant weight.
What could go wrong
This is a Phase 3 trial, but results are not yet known. The drug may not work better than placebo, and side effects are possible. Long-term safety and effectiveness are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

755 people

The number who actually took part.

Started

Jan 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Male or female subjects aged≥18years and≤75 years at the time of signing the ICF. * 2.At screening and prior to randomization, BMI must meet one of the following criteria: 1. BMI≥28kg/m²regardless of comorbidities； 2. BM≤24 kg/m² and\<28 kg/m², with at least one of the following comorbidities: prediabetes, hypertension, dyslipidemia, fatty liver disease, obstructive sleep apnea syndrome due to overweight, or weight-bearing joint pain. * 3.Weight change due to diet and exercise alone within 3 months prior to screening and randomization did not exceed 5%. Exclusion Criteria: * 1.Previously diagnosed obesity caused by monogenic mutations, other diseases, or medications. * 2.Previous diagnosis of diabetes; or HbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0 mmol/L at screening. * 3.Used of medicines or treatments that affect weight within 3 months prior to screening. * 4.History of acute or chronic pancreatitis, or pancreatic injury. * 5.History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history. * 6.History of depression/anxiety disorder, or prior diagnosis of moderate-to-severe anxiety/depressive state, or history of severe psychiatric disorders; * 7\. PHQ-9 scale score is ≥ 15 at screening; * 8\. Screening C-SSRS questionnaire suicide ideation response of "Category 4 or 5," or any "yes" response to suicidal behavior questions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight/obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight/obesity

Contacts and locations

Locations

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijiing, 100050, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, 256603, China

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, 250000, China

  • First Hospital of Qinhuangdao

    Qinhuangdao, Hebei, 066000, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, 730099, China

  • Guangzhou Red Cross Hospital

    Guangzhou, Guangdong, 510235, China

  • Handan First Hospital

    Handan, Hebei, 056002, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, 150001, China

  • Hebei Petro China Cental Hospital

    Langfang, Hebei, 065000, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, 516008, China

  • Huzhou Central Hospital

    Huzhou, Zhejiang, 313000, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, 330006, China

  • Jilin Province FAW General Hospital

    Changchun, Jilin, 130011, China

  • Jincheng General Hospital

    Jincheng, Shanxi, 48006, China

  • Luoyang Third People's Hospital

    Luoyang, Henan, 471002, China

  • Nanjing Jiangning Hospital

    Nanjing, Jiangsu, 210000, China

  • Nanyang Second People's Hospital

    Nanyang, Henan, 473009, China

  • Peking University People's Hospital

    Beijing, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, 472000, China

  • The 2nd People's Hospital of Chengdu

    Chengdu, Sichuan, 610021, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, 221006, China

  • The Fifth People's Hospital of Shenyang

    Shenyang, Liaoning, 110023, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, 471000, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, 315010, China

  • The First Affiliated of Nanyang Medical College

    Nanyang, Henan, 473000, China

  • The First People's Hospital of Changde

    Changde, Hunan, 415003, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011, China

  • The Second Affiliated Hospotal of Guangxi Medical University

    Nanning, Guangxi, 530006, China

  • The Second Hospital of Hebei Medical University

    Shijiangzhuang, Hebei, 050005, China

  • The Second People's Hospital of Lianyungang

    Lianyungang, Jiangsu, 222002, China

  • The Second People's Hospital of Yibin

    Yibin, Sichuan, 644000, China

  • The Third Affiliated Hospital of Jinzhou Medical University

    Jinzhou, Liaoning, 121002, China

  • Wuhan No.3 Hospital

    Wuhan, Hubei, 430060, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, 710000, China

  • Xuancheng People's Hospital

    Xuancheng, Anhui, 242099, China

  • Yan'an University Xianyang Hospital

    Yanan, Shanxi, 712000, China

  • Yichang Central People's Hospital

    Yichang, Hubei, 443003, China

  • Yichang Central People's Hospital (Xiling Campus)

    Yichang, Hubei, 443000, China

  • Yueyang Central Hospital

    Yueyang, Hunan, 414000, China

  • Yueyang People's Hospital

    Yueyang, Hunan, 414022, China

  • Yuncheng Central Hospital

    Yuncheng, Shanxi, 44099, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, 412007, China

  • Zibo Central Hospital

    Zibo, Shandong, 255036, China

  • Zibo Municipal Hospital

    Zibo, Shandong, 255400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.